Literature DB >> 10337029

Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients.

E Menegatti1, D Roccatello, K Fadden, G Piccoli, G De Rosa, L M Sena, A Rifai.   

Abstract

Leukotrienes (LT) of the 5-lipoxygenase pathway constitute a class of potent biological lipid mediators of inflammation implicated in the pathogenesis of different models of experimental glomerulonephritis. The key enzyme, 5-lipoxygenase (5-LO), catalyses oxygenation of arachidonic acid to generate the primary leukotriene LTA4. This LT, in turn, serves as a substrate for either LTA4 hydrolase, to form the potent chemoattractant LTB4, or LTC4 synthase, to produce the powerful vasoconstrictor LTC4. To investigate the potential role of LT in the pathogenesis of human glomerulonephritis with nephrotic syndrome, we examined the gene expression of 5-LO and LTA4 hydrolase in renal tissue of 21 adult patients with nephrotic syndrome and 11 controls. The patients consisted of 11 cases of membranous nephropathy (MN), seven focal and segmental glomerulosclerosis (FSGS), two non-IgA mesangial glomerulonephritis and one minimal change disease. Total RNA purified from renal tissue was reverse transcribed into cDNA and amplified with specific primers in a polymerase chain reaction (RT-PCR). Eight patients' renal tissue, four MN and four FSGS, co-expressed 5-LO and LTA4 hydrolase. In situ hybridization analysis revealed 5-LO expression and distribution limited to the interstitial cells surrounding the peritubular capillaries. Comparative clinical and immunohistological data showed that these eight patients had impaired renal function and interstitial changes that significantly correlated with 5-LO expression. These findings suggest that leukotrienes may play an important role in the pathogenesis of MN and FSGS. These results are also relevant to elucidating the pathophysiologic mechanisms which underlie progression to renal failure in these diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10337029      PMCID: PMC1905289          DOI: 10.1046/j.1365-2249.1999.00858.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  Tubulointerstitial injury following glomerulonephritis.

Authors:  J Yee; G S Kuncio; E G Neilson
Journal:  Semin Nephrol       Date:  1991-05       Impact factor: 5.299

2.  Human B lymphocytes possess 5-lipoxygenase activity and convert arachidonic acid to leukotriene B4.

Authors:  P J Jakobsson; B Odlander; D Steinhilber; A Rosén; H E Claesson
Journal:  Biochem Biophys Res Commun       Date:  1991-07-15       Impact factor: 3.575

3.  Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis.

Authors:  R J Glasser; J A Velosa; A F Michael
Journal:  Lab Invest       Date:  1977-05       Impact factor: 5.662

Review 4.  Tubulointerstitial changes as a major determinant in the progression of renal damage.

Authors:  K A Nath
Journal:  Am J Kidney Dis       Date:  1992-07       Impact factor: 8.860

5.  Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril.

Authors:  L Orning; G Krivi; G Bild; J Gierse; S Aykent; F A Fitzpatrick
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

6.  Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis.

Authors:  A Rifai; H Sakai; M Yagame
Journal:  Kidney Int Suppl       Date:  1993-01       Impact factor: 10.545

7.  Eicosanoid forming enzyme mRNA in human tissues. Analysis by quantitative polymerase chain reaction.

Authors:  C D Funk; G A FitzGerald
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

8.  Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rat.

Authors:  K F Badr; C Baylis; J M Pfeffer; M A Pfeffer; R J Soberman; R A Lewis; K F Austen; E J Corey; B M Brenner
Journal:  Circ Res       Date:  1984-05       Impact factor: 17.367

9.  Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis.

Authors:  T Katoh; E A Lianos; M Fukunaga; K Takahashi; K F Badr
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  On the expression and regulation of 5-lipoxygenase in human lymphocytes.

Authors:  P J Jakobsson; D Steinhilber; B Odlander; O Rådmark; H E Claesson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

View more
  6 in total

1.  Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations.

Authors:  Angela M Zivkovic; Jun Yang; Katrin Georgi; Christine Hegedus; Malin L Nording; Aifric O'Sullivan; J Bruce German; Ronald J Hogg; Robert H Weiss; Curt Bay; Bruce D Hammock
Journal:  Metabolomics       Date:  2012-12       Impact factor: 4.290

2.  Autosomal Recessive Congenital Ichthyosis and Steroid-Resistant Nephrotic Syndrome due to Homozygous Mutation in the ALOX12B gene: A Novel Association with Review of Literature.

Authors:  Lesa Dawman; Anit Kaur; Ritambhra Nada; Soumalya Chakraborty; Sanjeev Handa; Indar Kumar Sharawat; Karalanglin Tiewsoh
Journal:  J Pediatr Genet       Date:  2020-10-19

3.  Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial.

Authors:  Magdy Mohamed Zedan; Ahmed El-Refaey; Hosam Zaghloul; Mohamed E A Abdelrahim; Amal Osman; Mohamed M Zedan; Nashwa Eltantawy
Journal:  J Nephrol       Date:  2016-03-31       Impact factor: 3.902

4.  Uteroglobin gene polymorphism (G38A) may be a risk factor in childhood idiopathic nephrotic syndrome.

Authors:  Beltinge Demircioglu Kılıc; Mithat Buyukcelik; Sibel Oguzkan Balcı; Sacide Pehlivan; Seval Kul; Nilgun Col; Ayse Balat
Journal:  Pediatr Nephrol       Date:  2017-09-30       Impact factor: 3.714

5.  5-Lipoxygenase and leukotriene A4 hydrolase expression in primary nephrotic syndrome.

Authors:  A Bakr; S Hawas; S Slem; A Abdel Moniem; T Ghatab; M Tawfik
Journal:  Pediatr Nephrol       Date:  2004-02-21       Impact factor: 3.714

6.  Physiological and molecular effects of interleukin-18 administration on the mouse kidney.

Authors:  Kyosuke Yamanishi; Keiichiro Mukai; Takuya Hashimoto; Kaoru Ikubo; Keiji Nakasho; Yosif El-Darawish; Wen Li; Daisuke Okuzaki; Yuko Watanabe; Tetsu Hayakawa; Hiroshi Nojima; Hiromichi Yamanishi; Haruki Okamura; Hisato Matsunaga
Journal:  J Transl Med       Date:  2018-03-07       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.